Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of DS-8201a in subjects with breast cancer
jRCT2080223637Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Antitumor activity (e.g., objective response rate per RECIST 1.1). Started Sep 2017; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223637.